Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma

Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin E who are candidates of omalizumab and mepol...

Full description

Saved in:
Bibliographic Details
Main Authors: Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:Farmacia Hospitalaria
Subjects:
Online Access:http://www.aulamedica.es/fh/pdf/11221.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!